Patent · US Active

PD-1/PD-L1 inhibitors

US10710986B2 · kind B2 · utility

2Cited by

5References

5Claims

0Family size

Assignee

Gilead Sciences, Inc. · US

Inventors

Evangelos Aktoudianakis · Redwood City, US
Aesop Cho · Mountain View, US
Zhimin Du · Belmont, US
Michael Graupe · Pacifica, US
Lateshkumar Thakorlal Lad · Belmont, US
Paulo A. Machicao Tello · San Mateo, US
Jonathan William Medley · San Mateo, US
Samuel E. Metobo · Foster City, US
Prasenjit Kumar Mukherjee · South San Francisco, US
Devan Naduthambi · San Bruno, US
Eric Q. Parkhill · San Francisco, US
Barton W. Phillips · San Mateo, US
Scott Preston Simonovich · Oakland, US
Neil H. Squires · San Francisco, US
Peiyuan Wang · San Mateo, US
William J. Watkins · Saratoga, US
Jie Xu · Foster City, US
Kin S. Yang · Foster City, US
Christopher Allen Ziebenhaus · San Francisco, US

Key dates

Filing date	Feb 12, 2019
Grant date	Jul 14, 2020
Priority date	—
Expiry date	Feb 12, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/2827
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.